PHAS PhaseBio Pharmaceuticals Inc

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for orphan diseases, today announced that Chief Executive Officer Jonathan P. Mow will present a company overview at the Cowen and Company 39th Annual Health Care Conference on Wednesday, March 13, at 10:40 a.m. EDT in Boston.

A live and archived version of the presentation will be available on the company’s website at https://investors.phasebio.com.

About PhaseBio

PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies to treat orphan diseases, with an initial focus on cardiopulmonary disorders. The company’s lead development candidate is PB2452, a novel reversal agent for the antiplatelet therapy ticagrelor. PhaseBio is also leveraging its proprietary elastin-like polypeptide (“ELP”) technology platform to develop therapies with the potential for less-frequent dosing and improved pharmacokinetics. PhaseBio’s second product candidate PB1046, which is based on ELP, is a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension.

PhaseBio is located in Malvern, PA and San Diego, CA. For more information, please visit www.phasebio.com.

Investor Contact:John SharpPhaseBio Pharmaceuticals, Inc. Chief Financial Officer(610) 981-6506john.sharp@phasebio.com

Media Contact:Sarah Hall6 Degrees(215) 313-5638shall@6degreespr.com